# **SAFETY DATA SHEETS**

This SDS packet was issued with item: 078605722

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078069568 078934021



UPDATED PRODUCT CODE: 022219 **VERSION DATE:** 7/2007

Page 1 of 4

# MATERIAL SAFETY DATA SHEET

------ 1. CHEMICAL PRODUCT and COMPANY IDENTIFICATION ---------

Product Name: **CHORULON®** Product Family: **BOVINE PHARMACETUTICALS** 

#### PRODUCT:

#### PRODUCT CODE:

022219

**CHORULON®** (CHORIONIC GONADOTROPIN FOR INJECTION)

#### SYNONYMS:

NA

<u>PRODUCT USE</u>: Refer to product insert for proper usage.

COMPANY ADDRESS - Intervet Inc - 29160 Intervet Millsboro - Millsboro, DE 19966

------2. COMPOSITION / INFORMATION on INGREDIENTS ------------

PRODUCT COMPONENT:	<u>CAS NUMBER:</u>	RTECS NUMBER
HUMAN CHORIONIC GONADOTROPIN (HCG)	9002-61-3	MD6953000
D-MANNITOL	69-65-8	OP2060000
MONOSODIUM PHOSPHATE	7558-79-4	WC4500000
DISODIUM PHOSPHATE	7558-80-7	WA1900000

Ingredients are not hazardous in the amounts present in product. See Registry of Toxic Effects of Chemical Substances (RTECS) for information regarding specific ingredients.

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS. ANIMAL: 1-800-345-4735 EXT. 104 24 HRS. CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. - 5:00 P.M. EST



UPDATED PRODUCT CODE: 022219 VERSION DATE: 7/2007

Page 2 of 4

ROUTES OF ENTRY: Dermal, Injection, Inhalation, Ingestion

ACUTE EFFECTS OF EXPOSURE: Exposure to powder or reconstituted product may cause irritation or allergic reaction at site of contact. Accidental injection may cause result in menorrhagia.

CRONIC EFFECTS OF EXPOSURE: None known

CARCENOGINIC EFFECTS: This product is not considered a carcinogen and is not listed by OSHA, IRAC or NTP.

------ 4. FIRST AID MEASURES ------

SKIN: Wash immediately affected area with soap and water. Contact a physician.

EYES: Immediately flush with plenty of water for fifteen minutes. Contact a physician

INHALATION: Remove to fresh air. If not breathing, give artificial respiration and call for medical help immediately.

INGESTION: Seek medical attention immediately.

INJECTION: Remove needle, wash injection site with soap and water, contact physician immediately.

FLAMMABILITY: Product is non-flammable

EXTINGUISHING METHODS: Use Water, Water Mist, Foam or Dry Chemical to extinguish fire.

FIRE FIGHTING INSTRUCTIONS: Wear full bunker gear, including SCBA, for fighting fires involving large quantities of this material. Keep upwind.

------ 6. ACCIDENTAL RELEASE MEASURES------- 6.

PROCEDURES IN CASE OF SPILL OR LEAK: Clean up spilled material. Place powder and broken vials in a secure container for disposal.

EMERGENCY:HUMAN, FIRE, SPILLORENVIRONMENTAL:1-800-228-5635EXT. 13224 HRS.ANIMAL:1-800-345-4735EXT.10424 HRS.CHEMTREC®FORCHEMICAL EMERGENCY SPILL, LEAK, FIRE:1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. - 5:00 P.M. EST



UPDATED PRODUCT CODE: 022219 VERSION DATE: 7/2007

Page 3 of 4

------ 7. HANDLING and STORAGE ------

STORAGE: Store at room temperature. Protect containers from damage.

SHELF LIFE: See expiration date on product label.

HANDLING PRECAUTIONS: Read and follow all package insert instructions. Protect containers from damage.

# ------ 8. EXPOSURE CONTROL / PERSONAL PROTECTION ------

EYES: Prevent eye contact by wearing appropriate eye protection for handling tasks.

SKIN: Avoid skin contact. Wear chemical resistant gloves, long-sleeves and trousers to prevent dermal contact.

RESPIRATOR PROTECTION: Under normal conditions of use, as stated in the product insert, no respiratory protection is necessary. However, if ventilation is inadequate or aerosol hazard exists; wear a NIOSH approved respirator.

# ------ 9. PHYSICAL and CHEMICAL PROPERTIES ------

APPEARANCE: White amorphous powder plus clear, odorless, sterile aqueous solution.

PH: Not Available

------ 10. STABILITY and REACTIVITY ------

CHEMICAL STABILITY: Stable

CONDITIONS TO AVOID: None known

INCOMPATABILITY: None Known

HAZARDOUS POLYMERIZATION: Will not occur

------ 11. TOXICOLOGICAL INFORMATION ------

Oral LD 50 Rat: *Not available* Intraperitoneal LD50 (rat): *Not available* 

EMERGENCY:

HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS. ANIMAL: 1-800-345-4735 EXT. 104 24 HRS. CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. - 5:00 P.M. EST



## UPDATED PRODUCT CODE: 022219 VERSION DATE: 7/2007

Page 4 of 4

Intraperitoneal LD50 (mouse): Not available

# ------ 12. ECOLOGICAL INFORMATION------

This product when used according to the insert direction, poses negligible impact on the environment.

Dispose in accordance with all applicable Federal, State and Local regulations.

------ 14. TRANSPORTATION ------

DOT SHIPPING INFORMATION: Not regulated by the DOT

------ 15. REGULATORY INFORMATION-------

STATE REGULATIONS: The following chemicals associated with the product are subject to the Right-To-Know regulations in these states: None known

US FEDERAL REGULATIONS: SARA 313: No components listed.

------16. OTHER INFORMATION ------

**DISCLAIMER:** 

The information contained herein is true and accurate to the best of the knowledge of Intervet Inc. However, all data, instructions and/or recommendations are made without guarantee. The buyer and handler assume all risk and liability of use, storage and/or handling of this product not in accordance with the terms of the product label.

Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460

# **MATERIAL SAFETY DATA SHEET**

## SECTION I – PRODUCT INFORMATION

<b>PRODUCT NAME:</b>	Chorulon
<b>OFFICIAL NAME:</b>	Chorionic Gonadotropin for Injection
<b>PRODUCT TYPE:</b>	Animal Drug
DIN #:	00781851

MANUFACTURER/SUPPLIER:

Intervet International BV The Netherlands **TELEPHONE:** 1-800-268-4257 **EMERGENCY #:** 1-800-345-4735 (only to be used after hours between 4:30pm - 8:30am) **FAX:** 1-888-498-4444

# SECTION II - INGREDIENT INFORMATION

INGREDIENTS	CAS #	RTECS #
Human Chorionic Gonadotropin (HCG)	9002-61-3	MD6953000
D-Mannitol	69-65-8	OP2060000
Monosodium Phosphate	7558-79-4	WC4500000
Disodium Phosphate	7558-80-7	WA1900000

Ingredients are not hazardous in amounts present in product. See Registry of Toxic Effects of Chemical Substances (RTECS) for information regarding specific ingredients.

# SECTION III – PHYSICAL DATA

BOILING POINT (°F): N.A.VOLATILE BY VOLUME (%): N.A.VAPOR PRESSURE (MM HG): N.A.VOLATILE BY VOLUME (%): N.A.VAPOR DENSITY (Air=1): N.A.EVAPORATION RATE (=1): N.A.SOLUBILITY IN WATER: SolubleSPECIFIC GRAVITY (Water=1): N.A.APPEARANCE AND ODOUR: White amorphous powder plus clear, odourless, sterile aqueous solution.

# SECTION IV - FIRE AND EXPLOSION DATA

 FLASH POINT (<sup>0</sup>F): Non-Flammable
 FLAMMABLE LIMITS - Lower: N.A.

 Method Used: N.A.
 Upper: N.A.

 EXTINGUISHER MEDIA: Water, extinguishing powder, carbon dioxide, foam.
 SPECIAL FIRE FIGHTING PROCEDURES: None

 UNUSUAL FIRE AND EXPLOSION HAZARDS: None
 Unusual fire fight fire

# SECTION V – HEALTH HAZARD DATA

EXPOSURE LIMITS: None Established INHALATION: Powder may cause allergic reaction. EYE CONTACT: Powder or reconstituted product may cause irritation. SKIN CONTACT: None INGESTION: None OTHER (Specify): Accidental injection may result in menorrhagia. LISTED AS A CARCINOGEN BY: NTP: Yes IARC: Yes OSHA: Yes No X No X No X

# SECTION V – HEALTH HAZARD DATA (CONT.)

### FIRST AID PROCEDURES:

In case of accidental injection, remove needle, wash injection site with soap and water. Contact physician **IMMEDIATELY**. In case of contact with eyes, flush eyes for 15 minutes with water; if irritation persists, contact physician.

# SECTION VI – REACTIVITY DATA

STABILITY: Stable . <u>X</u> Unstable: INCOMPATIBILITY (Materials to Avoid): None HAZARDOUS DECOMPOSITION PRODUCTS: None HAZARDOUS POLYMERIZATION: May occur:

Will not occur:

CONDITIONS TO AVOID: N.A.

CONDITIONS TO AVOID: N.A.

# SECTION VII – SPILL OR LEAK PROCEDURE

STEPS TO BE TAKEN: Sweep area; collect powder and broken vials in appropriate container for disposal, seal effectively and dispose; wash down area.

DISPOSAL METHODS: Incinerate open, used vials and cartons. To destroy outdated product, open vials and incinerate. At all times adhere to applicable local, state, and federal regulations for disposal.

# SECTION VIII - SPECIAL PROTECTION INFORMATION

Х

RESPIRATORY PROTECTION: N.A.

Type: N.A. VENTILATION: Local: N.A. Mechanical: N.A. EYE PROTECTION: N.A. PROTECTIVE GLOVES: N.A.

Special: N.A. Other: N.A.

#### OTHER PROTECTIVE EQUIPMENT: N.A.

# SECTION IX - STORAGE AND HANDLING PRECAUTIONS

STORAGE AND HANDLING: Store at or below room temperature, 25°C (77°F). Protect glass vials from breakage. OTHER PRECAUTIONS: Read and follow all label directions.

# SECTION X – ADDITIONAL INFORMATION

Product is not hazardous when used according to label directions. Once reconstituted, product should be used immediately. Unused solution should be disposed of properly and not saved for future use.

Caution: Federal law restricts this product to use by or on the order of a licensed veterinarian.

#### FOR ANIMAL USE ONLY

The information contained herein is true and accurate to the best of the knowledge of Intervet Canada Ltd. However, all data, instructions and/or recommendations are made without guarantee.

SIGNED: \_\_\_\_\_

DATE ISSUED: January 2, 2008



Merck & Co., Inc. One Merck Dr. Whitehouse Station, NJ 08889

# MATERIAL SAFETY DATA SHEET

Merck urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION				
MSDS NAME:	PREGNYL 1500E/A			
SYNONYM(S):	AMPUL MET GEVRIESDROOGD POEDER: MENGSEL VAN CHORIONGONADOTROFINE, CMC NA HV OPL. 2G/L, MANNITOL, NATRIUM H2 FOSFAAT.2AQ EN NATRIUM2 H FOSF.2AQ; PREGNYL 1500E/A			
MSDS NUMBER:	SP324027			
EMERGENCY NUMBER(S):	(908) 423-6000 (24/7/365) English Only			
	Transportation Emergencies - CHEMTREC: (800) 424-9300 (Inside Continental USA) (703) 527-3887 (Outside Continental USA)			
MERCK MSDS HELPLINE:	(800) 770-8878 (US and Canada) (908) 473-3371 (Worldwide) Monday to Friday, 9am to 5pm (US Eastern Time)			

# **SECTION 2. HAZARDS IDENTIFICATION**

EMERGENCY OVERVIEW Lyophilized powder, Hygroscopic White to off-white Odorless May cause sensitization by inhalation or skin contact. *Causes effects to:* endocrine system

#### POTENTIAL HEALTH EFFECTS:

The toxicological properties of this material have not been fully characterized in humans and animals. Therefore, laboratory or process control systems and appropriate work practices should be in place to minimize the potential for inhalation exposure, skin contact, eye contact, or ingestion when working with this material.

Gonadotrophin, Chorionic is a hypothalamic / pituitary hormone. Symptoms of exposure may include headache, tiredness, changes of mood, depression, restlessness, and edema. Overexposure by inhalation may be harmful.

## LISTED CARCINOGENS

Not listed as a carcinogen by OSHA, IARC, NTP or ACGIH.

### SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

CHEMICAL NAME:AMPUL WITH GONADOTROPHIN, CHORIONIC (APPROX. 15%)CHEMICAL FAMILY:Hypothalamic and pituitary hormones/ GonadotrophicPRODUCT USE:Pharmaceutical production and analysis

Obtained by Global Safety Management, Inc. (www.globalsafetynet.com)

Mixture.

#### CHEMICAL COMPOSITION

INGREDIENT	CAS NUMBER	PERCENT
Gonadotropin, Chorionic	9002-61-3	15

INHALATION:	Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a physician.
SKIN CONTACT:	In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.
EYE CONTACT:	In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.
INGESTION:	Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Center. If symptoms persist, consult a physician.

#### FLAMMABILITY DATA:

Flash Point:

Not determined (liquids) or not applicable (solids).

#### **EXPLOSION HAZARDS:**

Under normal conditions of use, this material does not present a significant fire or explosion hazard. However, like most organic compounds, this material may present a dust deflagration hazard if sufficient quantities are suspended in air. This hazard may exist where sufficient quantities of finely divided material are (or may become) suspended in air during typical process operations. An assessment of each operation should be conducted and suitable deflagration prevention and protection techniques employed. The sensitivity of this material to ignition by electrostatic discharges has not been determined. In the absence of testing data, all conductive plant items and operations personnel handling this material should be suitably grounded.

#### SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

#### SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO2), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

# SECTION 6. ACCIDENTAL RELEASE MEASURES

#### PERSONAL PRECAUTIONS:

Wear appropriate personal protective equipment as specified in Section 8. Keep personnel away from the clean-up area.

#### SPILL RESPONSE / CLEANUP:

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. For laboratories and small-scale operations, incidental spills within a hood or enclosure should be cleaned by using a HEPA filtered vacuum or wet cleaning methods as appropriate. For large dry or liquid spills or those spills outside enclosure or hood, appropriate emergency response personnel should be notified. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

### SECTION 7. HANDLING AND STORAGE

#### HANDLING:

Avoid dust generation. Keep containers adequately sealed during material transfer, transport, or when not in use. Wash face, hands, and any exposed skin after handling. Do not eat, drink, or smoke when using this substance or mixture.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

#### STORAGE:

Store at 2-8 deg C. Avoid moisture. Store in brown coloured glass bottles which are closed with a screw cap fitted with polyethylene inlay.

See Section 8 for exposure controls and additional safe handling information.

## **SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION**

The following guidance applies to the handling of the active ingredient(s) in this formulation.

#### OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 4: 1-10 mcg/m<sup>3</sup>. Materials in an OEB 4 category are considered high health hazards. The OEB is range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

#### OCCUPATIONAL EXPOSURE GUIDELINE (OEG):

Internal Occupational Exposure Limit of 1.3 mcg/m<sup>3</sup> for Gonadotropin, chorionic.

#### EXPOSURE CONTROLS

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

#### **RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):**

Respiratory Protection:	Respiratory protective equipment (RPE) may be required for certain laboratory and large-scale manufacturing tasks if potential airborne breathing zone concentrations of substances exceed the relevant exposure limit(s). Workplace risk assessment should be completed before specifying and implementing RPE usage. Potential exposure points and pathways, task duration and frequency, potential employee contact with the substance, and the ability of the substance to be rendered airborne during specific tasks should be evaluated. Initial and ongoing strategies of quantitative exposure measurement should be obtained as required by the workplace risk assessment. All RPE must conform to local and regional specifications for efficacy and performance. Consult your site or corporate health and safety professional for additional guidance.
Skin Protection:	Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
Eye Protection:	Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard, potential for contact, or level of exposure. Consult your site safety staff for guidance.
Body Protection:	In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.
	In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.
	EXPOSURE LIMIT VALUES

See Internal Occupational Exposure Limit listed above.

MSDS NUMBER: SP324027

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

FORM: COLOR: ODOR: SOLUBILITY: Water: Lyophilized powder, Hygroscopic White to off-white Odorless

Insoluble

See Section 5 for flammability/explosivity information.

### SECTION 10. STABILITY AND REACTIVITY

#### STABILITY/ REACTIVITY:

Stable under normal conditions.

#### INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:

None known.

#### HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:

No dangerous decomposition is expected if used according to manufacturer's specifications.

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### ECOTOXICITY DATA

INGREDIENT ECOTOXICITY

Gonadotrophin, Chorionic: LOEC (21 days): 3ug/L (Fish, Anguilla anguilla) Endpoint: hormone change.

#### **ENVIRONMENTAL DATA**

There are no environmental data available for this material.

## SECTION 11. TOXICOLOGICAL INFORMATION

#### ACUTE TOXICITY DATA

INHALATION: No data available.

SKIN: No data available.

**EYE:** No data available.

ORAL: No data available.

#### **DERMAL AND RESPIRATORY SENSITIZATION:** No data available.

#### REPEAT DOSE TOXICITY DATA

SUBCHRONIC / CHRONIC TOXICITY: No data available.

#### REPRODUCTIVE / DEVELOPMENTAL TOXICITY:

Gonadotrophin, Chorionic showed reproductive disorders in humans and animal studies, and impairment of pre- and post-implantation development in mice. Female pigs dosed intravenously with 0.883 mg/kg 2 days pre-mating showed effects on fertility. Female monkeys dosed intramuscularly with 0.224 mg/kg 18 - 36 days after conception showed maternal effects. Rats dosed intravenously at 8.89 mg/kg 1 day pre-mating showed effects on fertility.

### MUTAGENICITY / GENOTOXICITY:

No data available.

#### CARCINOGENICITY:

This material or product has not been evaluated for carcinogenicity.

MSDS NAME: PREGNYL 1500E/A

Latest Revision Date: 26-Jan-2012

Page 4 of 5

MSDS NUMBER: SP324027

### SECTION 13. DISPOSAL CONSIDERATIONS

#### MATERIAL WASTE:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

#### PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

### **SECTION 14. TRANSPORT INFORMATION**

This material is not subject to the transportation regulations of DOT, IATA, IMO, and the ADR.

#### **SECTION 15. REGULATORY INFORMATION**

#### **TSCA LISTING**

This material or product is not subject to TSCA requirements.

#### **U.S. STATE REGULATIONS**

Check state requirements for ingredient listing.

#### **SECTION 16. OTHER INFORMATION**

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

#### DEPARTMENT ISSUING MSDS:

MERCK MSDS HELPLINE:

**MSDS CREATION DATE:** 

SUPERSEDES DATE:

SIGNIFICANT CHANGES (US SUBFORMAT):

Global Safety & the Environment Merck & Co., Inc. One Merck Drive Whitehouse Station, NJ 08889

(800) 770-8878 (US and Canada) (908) 473-3371 (Worldwide) Monday to Friday, 9am to 5pm (US Eastern Time)

07-Jul-2008

16-Dec-2010

Conversion, OEB

#### Intervet

#### CHORULON(R) (CHORIONIC GONADOTROPIN FOR INJECTION)

1. CHEMICAL PRODUCT		
Product Name: CHORULON(R) Product Family: BOVINE PH		
PRODUCT:		PRODUCT CODE:
CHORULON(R) (CHORIONIC GONADOTROPIN : SYNONYMS: NA	FOR INJECTION)	CH-475-1
PRODUCT USE: Refer to pro- COMPANY ADDRESS- Intervet Millsboro, DE. 19966	Inc - 405 State	Street -
2. COMPOSITION /	INFORMATION on I	NGREDIENTS
PRODUCT COMPONENT:	CAS NUMBER:	RTECS NUMBER
HUMAN CHORIONIC GONADOTROPIN (HCG)	9002-61-3	MD6953000
D-MANNITOL	69-65-8	OP2060000
MONOSODIUM PHOSPHATE	7558-79-4	WC4500000
DISODIUM PHOSPHATE	7558-80-7	WA1900000
Ingredients are not hazar product. See Registry of		
Substances (RTECS) for i		
ingredients.		
3. HAZAR	DS IDENTIFICATIO	
ROUTES OF ENTRY: Dermal, ACUTE EFFECTS OF EXPOSURE reconstituted product m reaction at site of con cause result in menorrh. CHRONIC EFFECTS OF EXPOSU CARCINOGENIC EFFECTS: Thi carcinogen and is not l	: Exposure to po ay cause irritat tact. Accidental agia. RE: None known s product is not	wder or ion or allergic injection may considered a
4 FTR	ST AID MEASURES	
SKIN: Wash immediately af Contact a physician.	fected area with	soap and water.
EYES: Immediately flush w minutes. Contact a phys		ter for fifteen
INHALATION: Remove to fre artificial respiration		
immediately. INGESTION: Seek medical a	ttention immedia	telv.
INJECTION: Remove needle, water, contact physicia	wash injection n immediately.	-
	FIGHTING MEASURE	
EXTINGUISHING METHODS: Us Chemical to extinguish	e Water, Water M	
FIRE FIGHTING INSTRUCTION including SCBA, for fig quantities of this mate	hting fires invo rial. Keep upwin	lving large d.
	AL RELEASE MEASU	
PROCEDURES IN CASE OF SPI		
material. Place powder of container for disposal.	and broken vials	in a secure
7. HAND	LING and STORAGE	
STORAGE: Store at room te		
damage. SHELF LIFE: See expiration HANDLING PRECAUTIONS: Rea instructions. Protect c	d and follow all	package insert

8. EXPOSURE CONTROL / PERSONAL PROTECTION
EYES: Prevent eye contact by wearing appropriate eye protection for handling tasks. SKIN: Avoid skin contact. Wear chemical resistant gloves, long-sleeves and trousers to prevent dermal contact.
RESPIRATOR PROTECTION: Under normal conditions of use, as stated in the product insert, no respiratory protection is necessary. However, if ventilation is inadequate or aerosol hazard exists; wear a NIOSH approved respirator.
9. PHYSICAL and CHEMICAL PROPERTIES
APPEARANCE: White amorphous powder plus clear, odorless, sterile aqueous solution. pH: Not Available
10. STABILITY and REACTIVITY
CHEMICAL STABILITY: Stable CONDITIONS TO AVOID: None known
INCOMPATIBILITY: None Known
HAZARDOUS POLYMERIZATION: Will not occur
11. TOXICOLOGICAL INFORMATION
Oral LD 50 Rat: Not available
Intraperitoneal LD50 (rat): Not available Intraperitoneal LD50 (mouse): Not available
12. ECOLOGICAL INFORMATION
This product when used according to the insert direction, poses negligible impact on the environment.
13. DISPOSAL CONSIDERATIONS
Dispose in accordance with all applicable Federal, State and Local regulations.
14. TRANSPORTATION
DOT SHIPPING INFORMATION: Not regulated by the DOT
15. REGULATORY INFORMATION
STATE REGULATIONS: The following chemicals associated with the product are subject to the Right-To-Know regulations in these states: None known US FEDERAL REGULATIONS: SARA 313: No components listed.
16. OTHER INFORMATION
DISCLAIMER: The information contained herein is true and accurate to the best of the knowledge of Intervet Inc. However, all data, instructions and/or recommendations are made without guarantee. The buyer and handler assume all
risk and liability of use, storage and/or handling of this product not in accordance with the terms of the product label.
EMERGENCY:

PRODUCT INFORMATION: 1-800-441-8272 OR 1-302-934-805 8:00 A.M. - 5:00 P.M. EST

#### CHORULON(R) (CHORIONIC GONADOTROPIN FOR INJECTION)

DISCLAIMER OF EXPRESSED AND IMPLIED WARRANTIES: although preparer and owner have taken reasonable care in the preparation of this document, we extend no warranties and make no representation as to the accuracy or completeness of the information contained herein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequences of its use. Each user should make a determination as to the suitability of the information for their particular purpose(s). A request has been made to the manufacturer to approve the contents of this material safety data sheet. Upon receipt of any changes a new MSDS will be made available.

COMPAS Code: 46500020



Versior 5.2	n	Revision Date: 06/12/2017		OS Number: 144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
SECTI	<b>ON</b> 1.	. IDENTIFICATION			
Pr	roduct	t name	:	Human Chorionic	Gonadotropin Formulation
Pr	roduct	t code	:	PREGNYL	
M	lanufa	acturer or supplier's	deta	ails	
Co	ompa	ny name of supplier	:	Merck & Co., Inc	
Ac	ddres	S	:	2000 Galloping H Kenilworth - New	ill Road Jersey - USA 1685
Τe	elepho	one	:	908-740-4000	
Τe	elefax		:	908-735-1496	
Er	merge	ency telephone	:	1-908-423-6000	
E-	-mail a	address	:	EHSDATASTEW	ARD@merck.com
Re	ecom	mended use of the c	:hen	nical and restriction	ons on use
		mended use	:	Pharmaceutical	
G	HS cl	. HAZARDS IDENTIF assification in accor stible dust			910.1200
Re	eprod	uctive toxicity	:	Category 1A	
sy	•	c target organ ic toxicity - repeated re	:	Category 1 (ovari	es)
G	HS la	bel elements			
Ha	azard	pictograms	:		
Si	ignal \	Word	:	Danger	
Ha	azard	Statements	:	handling or by oth concentrations in H360Fd May dam unborn child.	nage fertility. Suspected of damaging the mage to organs (ovaries) through prolonged or



Version 5.2	Revision Date: 06/12/2017	SDS Number: 22144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014		
Preca	utionary Statements	<ul> <li>Prevention:</li> <li>P201 Obtain special instructions before use.</li> <li>P202 Do not handle until all safety precautions have been read and understood.</li> <li>P260 Do not breathe dust.</li> <li>P264 Wash skin thoroughly after handling.</li> <li>P270 Do not eat, drink or smoke when using this product.</li> <li>P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.</li> </ul>			
		<b>Response:</b> P308 + P313 IF attention.	exposed or concerned: Get medical advice/		
		<b>Storage:</b> P405 Store locl	ked up.		
		<b>Disposal:</b> P501 Dispose o posal plant.	of contents/ container to an approved waste dis-		

# Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

# SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

## Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Gonadotropin, chorionic	9002-61-3	>= 90 -< 100

# **SECTION 4. FIRST AID MEASURES**

General advice	<ul> <li>In the case of accident or if you feel unwell, seek medical advice immediately.</li> <li>When symptoms persist or in all cases of doubt seek medical advice.</li> </ul>
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	<ul> <li>In case of contact, immediately flush skin with soap and plenty of water.</li> <li>Remove contaminated clothing and shoes.</li> <li>Get medical attention.</li> <li>Wash clothing before reuse.</li> <li>Thoroughly clean shoes before reuse.</li> </ul>
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.



Version 5.2	Revision Date: 06/12/2017	SDS Number: 22144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
lf swa	llowed	Get medical atte	D NOT induce vomiting. ention. proughly with water.
	important symptoms ffects, both acute and ed	the skin. Dust contact wit May damage fe child.	st can cause mechanical irritation or drying of th the eyes can lead to mechanical irritation. rtility. Suspected of damaging the unborn e to organs through prolonged or repeated
Prote	ction of first-aiders	and use the rec	ders should pay attention to self-protection, ommended personal protective equipment tial for exposure exists.
Notes	to physician	: Treat symptoma	atically and supportively.

# SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Sulfur oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

# SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer- gency procedures	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions :	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so.



Version 5.2	Revision Date: 06/12/2017		S Number: 144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
Motho	do and motorials for		Local authorities cannot be contain	
	ds and materials for nment and cleaning up	:	container for disp Avoid dispersal o with compressed Dust deposits sho surfaces, as these released into the Local or national disposal of this m employed in the o determine which Sections 13 and	f dust in the air (i.e., clearing dust surfaces

# SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.	
Local/Total ventilation	:	Use with local exhaust ventilation.	
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.	
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.	
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases	



Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
5.2	06/12/2017	22144-00008	Date of first issue: 10/15/2014

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Gonadotropin, chorionic	9002-61-3	TWA	3 µg/m3	Merck
		Wipe limit	25 µg/100 cm <sup>2</sup>	Merck
		TWA	OEB 4	Merck

Engineering measures :	Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). Use with local exhaust ventilation. Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m3 - total dust, 5 mg/m3 - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m3 - respirable particles, 10 mg/m3 - inhalable particles.
Personal protective equipment	
Respiratory protection :	General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
Hand protection Material :	Chemical-resistant gloves
Remarks :	Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the



Version 5.2	Revision Date: 06/12/2017		DS Number: 144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
				micals of the aforementioned protective love manufacturer. Wash hands before e end of workday.
Eye p	rotection	:	Wear the followin Safety goggles	g personal protective equipment:
Skin a	nd body protection	:	resistance data a potential. Skin contact mus	e protective clothing based on chemical nd an assessment of the local exposure t be avoided by using impervious protective aprons, boots, etc).
Hygie	ne measures	:	located close to t When using do n	lushing systems and safety showers are he working place. ot eat, drink or smoke. ted clothing before re-use.

# SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white
Odor	:	odorless
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available



Version 5.2	Revision Date: 06/12/2017		S Number: 144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
Rel	ative density	:	No data available	e
	ubility(ies) Water solubility	:	soluble	
	tition coefficient: n- anol/water	:	No data available	9
Aut	oignition temperature	:	No data available	9
Dec	composition temperature	:	No data available	9
	cosity Viscosity, kinematic	:	No data available	e e e e e e e e e e e e e e e e e e e
Exp	losive properties	:	Not explosive	
Oxi	dizing properties	:	The substance o	r mixture is not classified as oxidizing.
Mol	ecular weight	:	No data available	9
Par	ticle size	:	No data available	9

# SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

# SECTION 11. TOXICOLOGICAL INFORMATION

## Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## Acute toxicity

Not classified based on available information.

# Skin corrosion/irritation

Not classified based on available information.

# SAFETY DATA SHEET



# Human Chorionic Gonadotropin Formulation

rsion 2	Revision Date: 06/12/2017	SDS Number: 22144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
Serio	us eye damage/eye irı	itation	
	lassified based on avail		
Resp	iratory or skin sensitiz	zation	
Skin	sensitization		
Not c	lassified based on avail	able information.	
Resp	iratory sensitization		
Not c	lassified based on avail	able information.	
Germ	cell mutagenicity		
Not c	lassified based on avail	able information.	
Carci	nogenicity		
Not cl IARC	lassified based on avail	No ingredient of	f this product present at levels greater than or s identified as probable, possible or confirmed gen by IARC.
OSH	A		of this product present at levels greater than or s on OSHA's list of regulated carcinogens.
NTP		equal to 0.1% is	f this product present at levels greater than or s identified as a known or anticipated carcinoger
-	oductive toxicity damage fertility. Suspec	by NTP. ted of damaging th	ne unborn child.
May o Ingre	damage fertility. Suspec dients:	·	ne unborn child.
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th	
May o Ingre Gona	damage fertility. Suspec dients:	ted of damaging th : Test Type: F	ertility
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F	ertility : Route: Intravenous injection
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F	ertility Route: Intravenous injection NEL: 8.89 mg/kg body weight
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application R Fertility: LOA Result: Effec	ertility Route: Intravenous injection NEL: 8.89 mg/kg body weight ets on fertility.
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F	ertility Route: Intravenous injection AEL: 8.89 mg/kg body weight ets on fertility.
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F Application F Fertility: LOA	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight ts on fertility. Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F Application F	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight ts on fertility. Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application R Fertility: LOA Result: Effec Test Type: F Application R Fertility: LOA Result: Effec Test Type: F	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight ts on fertility. Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight ts on fertility.
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application R Fertility: LOA Result: Effec Test Type: F Application R Fertility: LOA Result: Effec Test Type: F Species: More	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight ts on fertility. Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight ts on fertility.
May o Ingre Gona	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F Application F Fertility: LOA Result: Effec Test Type: F Species: Mon Fertility: LOA	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight ts on fertility. Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight ts on fertility.
May o Ingre Gona Effect	damage fertility. Suspec dients: idotropin, chorionic: is on fertility	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F Application F Fertility: LOA Result: Effec Test Type: F Species: Mon Fertility: LOA Result: Effec	ertility Route: Intravenous injection AEL: 8.89 mg/kg body weight ets on fertility. Fertility Route: Intraperitoneal injection AEL: 0.883 mg/kg body weight ets on fertility. Fertility nkey AEL: 0.224 mg/kg body weight ets on fertility.
May o Ingre Gona Effect	damage fertility. Suspec <u>dients:</u> idotropin, chorionic:	ted of damaging th : Test Type: F Species: Rat Application F Fertility: LOA Result: Effec Test Type: F Application F Fertility: LOA Result: Effec Test Type: F Species: Mon Fertility: LOA Result: Effec : Test Type: E Species: Har	ertility Route: Intravenous injection AEL: 8.89 mg/kg body weight ets on fertility. Fertility Route: Intraperitoneal injection AEL: 0.883 mg/kg body weight ets on fertility. Fertility nkey AEL: 0.224 mg/kg body weight ets on fertility.
May o Ingre Gona Effect	damage fertility. Suspec dients: idotropin, chorionic: is on fertility	ted of damaging th : Test Type: F Species: Rat Application R Fertility: LOA Result: Effec Test Type: F Application R Fertility: LOA Result: Effec Test Type: F Species: Mon Fertility: LOA Result: Effec : Test Type: E Species: Har Application R	ertility Route: Intravenous injection XEL: 8.89 mg/kg body weight tes on fertility. Pertility Route: Intraperitoneal injection XEL: 0.883 mg/kg body weight tes on fertility. Pertility NEL: 0.224 mg/kg body weight tes on fertility. MEL: 0.224 mg/kg body weight tes on fertility.
May o Ingre Gona Effect	damage fertility. Suspec dients: idotropin, chorionic: is on fertility	ted of damaging the : Test Type: F Species: Rat Application R Fertility: LOA Result: Effec Test Type: F Application R Fertility: LOA Result: Effec Test Type: F Species: Mon Fertility: LOA Result: Effec : Test Type: E Species: Har Application R Embryo-fetal	ertility Route: Intravenous injection AEL: 8.89 mg/kg body weight ets on fertility. Fertility Route: Intraperitoneal injection AEL: 0.883 mg/kg body weight ets on fertility. Fertility nkey AEL: 0.224 mg/kg body weight ets on fertility.



Version 5.2	Revision Date: 06/12/2017	SDS Number: 22144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014		
sessr	sessment		fertility from human epidemiological studies., Some evidence of adverse effects on development, based on animal experiments.		
STO	<b>F-single exposure</b>				
Not c	lassified based on ava	ailable information.			
	<b>F</b> -repeated exposure				
		(ovaries) through prole	onged or repeated exposure.		
Ingre	edients:				
Targe	adotropin, chorionic: et Organs: ovaries ssment: Causes dama		prolonged or repeated exposure.		
-	ration toxicity lassified based on ava	ailable information			
	rience with human e				
Ingre	edients:				
Gona	adotropin, chorionic:				
Inhala	ation		ovaries ects on menstruation, gynecomastia, Head- epression, Irritability, restlessness, Fatigue		
SECTION	12. ECOLOGICAL IN	IFORMATION			
Ecot	oxicity				
No da	No data available				

# No data available

Persistence and degradability

**Bioaccumulative potential** 

No data available

No data available **Mobility in soil** No data available

Other adverse effects

# SECTION 13. DISPOSAL CONSIDERATIONS

<b>Disposal methods</b> Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.



Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
5.2	06/12/2017	22144-00008	Date of first issue: 10/15/2014

## **SECTION 14. TRANSPORT INFORMATION**

### International Regulations

### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

#### 49 CFR

Not regulated as a dangerous good

## **SECTION 15. REGULATORY INFORMATION**

## **EPCRA - Emergency Planning and Community Right-to-Know**

### **CERCLA Reportable Quantity**

Ingredients	CAS-No.	Component RQ	Calculated product RQ
		(lbs)	(lbs)
Sodium phosphate, dihydrate	10028-24-7	5000	*

\*: Calculated RQ exceeds reasonably attainable upper limit.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Fire Hazard Chronic Health Hazard
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## **US State Regulations**

Pennsylvania Right To Know		
Gonadotropin, chorionic Sodium phosphate, dihydrate	9002-61-3 10028-24-7	
oodiani phosphate, anyarate	10020 24 1	

### California Prop. 65


This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

### The ingredients of this product are reported in the following inventories:



Version 5.2	Revision Date: 06/12/2017	SDS Number: 22144-00008	Date of last issue: 04/28/2017 Date of first issue: 10/15/2014
AICS		: not determined	1
DSL		: not determined	1
IECSO	C	: not determined	3

# **SECTION 16. OTHER INFORMATION**



## Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-



Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
5.2	06/12/2017	22144-00008	Date of first issue: 10/15/2014

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Revision Date : 06/12/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8